Northpond Ventures
Northpond Ventures is a science-driven venture capital firm based in Bethesda, Maryland, with additional offices in San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the firm concentrates its investments in life sciences, diagnostics, therapeutics, digital health, and related technologies, including AI and machine learning applications in biotech and medical fields, as well as environmental and other emerging technologies. It seeks to back early- and growth-stage companies that advance biomedical research, diagnostics, medical devices, and technology-enabled health solutions. The firm operates as a registered investment adviser and emphasizes building a better tomorrow through science-driven investing. It focuses on strategy, value creation, and supporting companies at the intersection of life sciences and technology, aiming to accelerate innovations that improve health outcomes.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Maryland
Personal Genome Diagnostics
Series C in 2021
Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.
Delfi Diagnostics
Series A in 2021
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.